BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AVIR catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:a1e485b39e12a00ac2ec@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:AVIR P3 readout (est.): C-Forward: Efficacy and Safety of BEM/RZR v
 s SOF/VEL in Subjects With Chronic HCV
DESCRIPTION:C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subject
 s With Chronic HCV\nNCT07037277 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor
 : Atea Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker AVIR (confidence 0.9)\nSource: https://clinicaltrials.gov/
 study/NCT07037277\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07037277
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
